We study the mechanisms of neurodegeneration in optic nerve diseases, particularly glaucoma, and we are developing new treatments to protect and regenerate the optic nerve using gene therapy, stem cells and other approaches.
Major work focuses on development of effective gene therapy for glaucoma progressing towards blindness despite maximum conventional treatment and has been recognised with further funding following the team’s runners up position in the UK Government’s BioStart Synthetic Biology Competition. Working with patients with genetic eye diseases is enabling disease gene discovery, deep phenotyping and biomarker profiling leading to personalised therapies.
The Cambridge Ear Institute integrates translational research into very large clinical flow in the Otology, Neurology, Skull Base and Auditory Implants programme at
Addenbrooke’s hospital. We focus on objective measures of pathophysiological mechanisms underlying patient symptoms and disease manifestations, and have a very strong collaboration with the Department of Engineering. Current projects include developing novel sensors to measure electrical stimulation spread in cochlear implant models and patients, novel psychoacoustic and electrophysiology tests to determine auditory lesion site, development of wearable technologies to interrogate relevant physiology and its dysfunction in the patient’s environment, and new multimodal sensory tools for balance rehabilitation.